CDK4 and familial pancreatic carcinoma: Previous studies reported that CDK4/6 inhibitors also suppressed PDAC cell proliferation in vitro and in vivo [39], and some ongoing clinical trials are testing their efficacy in pancreatic cancer (ClinicalTrials.gov Identifier: NCT03065062, NCT04870034).